4.7 Article

GD2 CAR T cells against human glioblastoma

期刊

NPJ PRECISION ONCOLOGY
卷 5, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41698-021-00233-9

关键词

-

类别

资金

  1. project Dipartimenti Eccellenti MIUR 2017
  2. Diana Laneri post-doctoral fellowship
  3. Associazione ASEOP

向作者/读者索取更多资源

The study revealed that GD2 CAR has strong anti-tumor potential in glioblastoma models, and intracerebral CAR T injection significantly increased survival time without any side effects.
Glioblastoma is the most malignant primary brain tumor and is still in need of effective medical treatment. We isolated patient-derived glioblastoma cells showing high GD2 antigen expression representing a potential target for CAR T strategy. Data highlighted a robust GD2 CAR antitumor potential in 2D and 3D glioblastoma models associated with a significant and CAR T-restricted increase of selected cytokines. interestingly, immunosuppressant TGF beta 1, expressed in all co-cultures, did not influence antitumor activity. The orthotopic NOD/SCID models using primary glioblastoma cells reproduced human histopathological features. Considering still-conflicting data on the delivery route for targeting brain tumors, we compared intracerebral versus intravenous CAR T injections. We report that the intracerebral route significantly increased the length of survival time in a dose-dependent manner, without any side effects. Collectively, the proposed anti-GD2 CAR can counteract human glioblastoma potentially opening a new therapeutic option for a still incurable cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据